Accumulate shares of Nebius (NBIS) around the $1.70 pullback level to capitalize on its massive $40 billion AI infrastructure backlog and discounted neocloud valuation. Buy Micron Technology (MU) while it trades at a cheap forward P/E of 4x to 5x earnings, as the market misprices its transition into a structural AI and robotics memory supplier. Purchase NVIDIA (NVDA) below $200 to capture an expected 62% revenue growth rate backed by its dominant CUDA platform and AI market leadership. Take advantage of the recent sell-off in Hims & Hers Health (HIMS) within the $27–$29 range to secure a high-growth, recession-resistant healthcare subscription model with over 2 million recurring subscribers. Finally, buy Meta Platforms (META) as the cheapest Magnificent Seven stock, though investors should exercise caution around upcoming earnings due to potential volatility over AI spending.

Nebius (NBIS)

• Evaluated as a top pick among "neoclouds" due to a cheaper valuation relative to peers like CoreWeave
• Possesses a large pipeline/backlog of roughly $40 billion, which includes major deals with Meta and Microsoft, plus an underreported billion-dollar deal scheduled for July 2026
• Advantages cited include a strong founding team (tied to Russia's Yandex), a 26% ownership stake in ClickHouse (potentially as valuable as Snowflake), and lower initial debt compared to competitors

Takeaways

• Considered a strong buying opportunity after pulling back to around $1.70 (from a high of $2.70), presenting an attractive entry point for investors looking at AI infrastructure

Micron Technology (MU)

• Trading at a remarkably low forward price-to-earnings (P/E) ratio of roughly 4x to 5x next 12 months' earnings, despite signing approximately 17 multi-year (five-year) supply deals
• The market continues to price Micron as a cyclical memory provider, but the host argues it is transitioning into a non-cyclical business driven by structural AI and humanoid robotics memory demand

Takeaways

• Viewed as fundamentally mispriced by the market, trading at valuations more typical of distressed legacy businesses despite massive projected earnings (roughly $1.55 EPS) and growing long-term demand

NVIDIA (NVDA)

• Described as surprisingly cheap, trading under $200 (specifically noted at $197) while sporting a market capitalization of $4.7 trillion (making it temporarily cheaper than Apple)
• Expected to grow next 12 months' revenue by 62%, powered by its dominant CUDA platform and foundational role in the AI revolution
• Considered a much better relative value than AMD based on internal valuation metrics

Takeaways

• Recommended as a cheap large-cap AI leader that has stagnated over a 10-month period despite massive underlying business growth and continued dominance in AI hardware

Hims & Hers Health (HIMS)

• Sold off sharply during macro/rate-hike fears down to the $27–$29 range, which the speaker views as irrational since healthcare subscription services (obesity pills, hair loss treatments) are typically recession-resistant
• Positioned to capitalize on the peptide market after acquiring the CS Bio manufacturing facility in California, anticipating approval for six out of seven reviewed peptides, including the popular recovery peptide BPC-157
• Features a high recurring revenue model (over 90% recurring) with more than 2 million subscribers

Takeaways

• Highlighted as heavily discounted due to short-term market "vibes" rather than fundamentals, offering strong long-term upside for investors comfortable with market volatility

Meta Platforms (META)

• Highlighted as the cheapest of the "Magnificent 7" stocks covered, trading at an enterprise value metric of 0.39
• Moving toward becoming a major cloud hyperscaler by monetizing its extra computing capacity, alongside adopting an X Premium style monetization strategy via paid subscriptions like Instagram Plus
• AI integration is successfully making ads and content more addictive across its multi-billion user family of apps

Takeaways

• Seen as an undervalued mega-cap opportunity, though investors should remain cautious around upcoming earnings announcements due to potential market overreactions regarding ongoing AI infrastructure spending